InterVenn Biosciences’ Post

I am excited 😎 to share my latest research on the development of a new anti-DLL4 Nanobody and its potential use as a prognostic tool for gastric cancer. Our study indicates that DLL4 expression is significantly linked to poor overall and recurrence-free survival in patients with gastric cancer. By using this particular Nanobody, we can improve the detection of DLL4 in tumor tissues, which could lead to the development of better prognostic models and targeted therapies. This breakthrough has the potential to result in improved treatment approaches and outcomes for individuals fighting gastric cancer. Check out the full article for more insights! 😊 https://lnkd.in/e2KTv4Mn

#SpeakingofScience: Freenome is at the forefront of #medicalinnovation, harnessing the power of #machinelearning to analyze #DNA, #RNA, proteins, and more in pursuit of detecting #cancer through cell-free #biomarkers. Their groundbreaking #multiomics platform, initially applied to #colorectalcancer, is now making waves in a 30,000-subject #clinicaltrial set to conclude this month. Now, Freenome is embarking on a second study focused on #lungcancer, enrolling 20,000 high-risk individuals eligible for #cancerscreening. The study aims for #FDA approval, and could offer an alternative to traditional CT screening. Join us in applauding Freenome's dedication to revolutionizing cancer diagnostics! 🚀🧬 #CancerDetection #MedicalInnovation #Freenome #HealthcareAdvancements https://lnkd.in/gQZUXc7z

Groundbreaking PPI data connect hypoxia and intracellular traffic in a breast cancer cell model The findings underline the importance of the HIF-1α/RAB22A interaction in linking hypoxia to intracellular trafficking and microvesicle/exosome generation within cancer cells for the first time. Increased exosome production under hypoxia can enhance cancer cell invasiveness and communication with the tumor microenvironment.The study provides a deeper understanding of the potential mechanisms by which HIF-1α, a key regulator of the hypoxic response, may regulate intracellular trafficking and exosome biogenesis in cancer cells. This novel interaction between HIF-1α and RAB22A offers insights into how hypoxia can mechanistically modulate the extracellular vesicle-mediated crosstalk between cancer cells and their microenvironment, which is crucial for tumor progression and metastasis.

Inhibitory anti-NBCn1 antibodies block net acid extrusion in human breast cancer tissue, particularly from patients with disseminated disease, and pH-dependently limit triple-negative breast cancer growth. https://lnkd.in/ejFmE7HD

NETs are not only thought to impair the efficacy of cancer immunotherapies using Immune Checkpoint Inhibitors but have also been implicated in impairing the efferocytosis response of tumors to Doxorubicin chemotherapy. This anti-cancer resistance may likewise be related to the simultaneous upregulation of the anti-phagocytic CD47 "don't eat me" overexpression. Targeting the removal of NET-trapped CTCs could potentially help circumvent this impaired CD47/NET-mediated inhibition of anti-cancer therapies and help facilitate tumor cell clearance. Neutrophil extracellular traps (NETs) reduce the diffusion of doxorubicin which may attenuate its ability to induce apoptosis of ovarian cancer cells https://lnkd.in/eWeKRUJf

Inhibitory anti-NBCn1 antibodies block net acid extrusion in human breast cancer tissue, particularly from patients with disseminated disease, and pH-dependently limit triple-negative breast cancer growth. https://lnkd.in/greXjvbJ

Inhibitory anti-NBCn1 antibodies block net acid extrusion in human breast cancer tissue, particularly from patients with disseminated disease, and pH-dependently limit triple-negative breast cancer growth. https://lnkd.in/d3aC8fMg

📢 Didn't attend our recent Xtalks webinar on Veracyte's Immunoscore IC® (CD8/PDL1)? No worries! The Veracyte Biopharma Services team welcomes you to watch the replay! hashtag#Immunotherapy has made remarkable progress in recent years, revolutionizing the way we fight hashtag#cancer. The identification and use of biomarkers that allow clinicians to tailor treatments to individual patients are key factors. In this session, the Immunoscore® Immune Checkpoint (CD8/PDL1) assay is showcased with an in-depth review of the assay's analytical performance, clinical relevance, and efficacy with a focus on metastatic colorectal cancer (#mCRC) and non-small cell lung cancer (#NSCLC). #DrugDevelopment #Innovation #XtalksWebinar 🎥 Click here to get access: https://lnkd.in/eQKACCAF

#ovariancancer #biomarkers #cancerresearch #oncology https://lnkd.in/dTetkDWa Abstract Background There is a need for diagnostic tests for #screening, triaging and staging of epithelial ovarian cancer (EOC). #Glycoproteomics of blood samples has shown promise for biomarker discovery. Methods We applied glycoproteomics to serum of people with EOC or benign pelvic masses and healthy controls. A total of 653 analytes were quantified and assessed in multivariable models, which were tested in an independent cohort. Additionally, we analyzed glycosylation patterns in serum markers and in tissues. Conclusions Blood glycopeptide biomarkers have the potential to distinguish benign from malignant pelvic masses, and early- from late-stage EOC. Glycosylation of circulating and tumor tissue proteins may be related. This study supports the hypothesis that blood glycoproteomic profiling can be used for EOC diagnosis and staging and it warrants further clinical evaluation.

📃Scientific paper: CYB561 promotes HER2+ breast cancer proliferation by inhibiting H2AFY degradation Abstract: Breast cancer (BRCA) has a high incidence and mortality rate among women. Different molecular subtypes of breast cancer have different prognoses and require personalized therapies. It is imperative to find novel therapeutic targets for different molecular subtypes of BRCA. Here, we demonstrated for the first time that Cytochromeb561 (CYB561) is highly expressed in BRCA and correlates with poor prognosis, especially in HER2-positive BRCA. Overexpression of CYB561 could upregulate macroH2A (H2AFY) expression in HER2-positive BRCA cells through inhibition of H2AFY ubiquitination, and high expression of CYB561 in HER2-positive BRCA cells could promote the proliferation and migration of cells. Furthermore, we have demonstrated that CYB561 regulates H2AFY expression, thereby influencing the expression of NF-κB, a downstream molecule of H2AFY. These findings have been validated through in vivo experiments. In conclusion, we propose that CYB561 may represent a novel therapeutic target for the treatment of HER2-positive BRCA. Graphical abstract CYB561 promotes the proliferation of HER2+ BRCA cells: CYB561 enhances the expression of H2AFY by inhibiting its ubiquitination, which leads to an increase expression of NF-κB in the nucleus. H2AFY, together with NF-κB, promotes the proliferation of HER2+ BRCA cells. Continued on ES/IODE ➡️ https://etcse.fr/04mq ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.